Medical devices, healthcare technology and the business of care
510(k) clearance · K260214

STA - Liquid Anti-Xa

Diagnostica Stago, Inc. · Decision date Sep 24, 2026

FDA DECISIONK260214

What did the FDA decide?

FDA records K260214 as a 510(k) premarket notification, with a decision dated Sep 24, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Hematology
Decision date
Sep 24, 2026

FDA source record

Regulatory record facts

Identifier
K260214
Regulatory pathway
510(k) premarket notification
Product code
KFF
Decision code
SESE
Decision date
Sep 24, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Assay, Heparin.

Product code
KFF
FDA device class
2

FDA decision timeline

  1. K260214 received

    Application receipt date recorded by FDA.

  2. K260214 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Diagnostica Stago, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Parsippany, NJ

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records